Tirzepatide - Generic Drug Details

What are the generic sources for tirzepatide and what is the scope of freedom to operate?

Tirzepatide is the generic ingredient in six branded drugs marketed by Eli Lilly And Co and is included in two NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tirzepatide has two hundred and one patent family members in forty-six countries.

One supplier is listed for this compound.

Summary for tirzepatide

International Patents:	201
US Patents:	8
Tradenames:	6
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	5
Clinical Trials:	166
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for tirzepatide
What excipients (inactive ingredients) are in tirzepatide?	tirzepatide excipients list
DailyMed Link:	tirzepatide at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for tirzepatide

Dosage:

SOLUTION;SUBCUTANEOUS

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for tirzepatide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
First Affiliated Hospital of Wenzhou Medical University	PHASE2
University of Virginia	PHASE3
University Medical Centre Ljubljana	PHASE4

See all tirzepatide clinical trials

Pharmacology for tirzepatide

Drug Class	GLP-1 Receptor Agonist Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Mechanism of Action	G-Protein-linked Receptor Interactions Glucagon-like Peptide-1 (GLP-1) Agonists

Anatomical Therapeutic Chemical (ATC) Classes for tirzepatide

A10BX	Other blood glucose lowering drugs, excl. insulins
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

US Patents and Regulatory Information for tirzepatide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	MOUNJARO (AUTOINJECTOR)	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-005	May 13, 2022		RX	Yes	Yes
Eli Lilly And Co	ZEPBOUND	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-010	Mar 28, 2024		RX	Yes	Yes
Eli Lilly And Co	ZEPBOUND (AUTOINJECTOR)	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-003	Nov 8, 2023		RX	Yes	Yes

EU/EMA Drug Approvals for tirzepatide

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Mounjaro	tirzepatide	EMEA/H/C/005620Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2022-09-15

International Patents for tirzepatide

Country	Patent Number	Title	Estimated Expiration
France	23C1006
South Korea	20250090374	GIP/GLP1 작용제 조성물 (GIP/GLP1 GIP/GLP1 AGONIST COMPOSITIONS)
Ukraine	118239	СПОЛУКА-КОАГОНІСТ GIP І GLP-1 (GIP AND GLP-1 CO-AGONIST COMPOUNDS)

Supplementary Protection Certificates for tirzepatide

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3242887	23C1006	France		PRODUCT NAME: TIRZEPATIDE; REGISTRATION NO/DATE: EU/1/22/1685 20220919
3242887	CA 2023 00005	Denmark		PRODUCT NAME: TIRZEPATID OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/22/1685 20220919
3242887	SPC/GB23/006	United Kingdom		PRODUCT NAME: TIRZEPATIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTERED: UK EU/1/22/1685(FOR NI) 20220919; UK MORE ON HISTORY TAB 20220919

TIRZEPATIDE: Market Dynamics and Financial Trajectory

Last updated: March 10, 2026

What is the current development status of Tirzepatide?

Tirzepatide is a novel dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It is designed for type 2 diabetes mellitus (T2DM) treatment and obesity management. As of 2023, the drug completed Phase 3 trials for diabetes and obesity indication. It received FDA breakthrough therapy designation in 2021, with a submission for approval expected in late 2023 or early 2024.

What are the key market drivers?

Increasing prevalence of type 2 diabetes and obesity

• Global T2DM prevalence: Estimated at 537 million adults in 2021, projected to reach 643 million by 2030 (IDF, 2023).
• Obesity rates: Over 650 million adults worldwide are obese, contributing substantially to T2DM cases.
• Market need: Reduced cardiovascular risk and weight loss benefits position Tirzepatide favorably against existing therapies such as semaglutide or dulaglutide.

Competitive landscape

• Existing drugs: Semaglutide (Wegovy, Ozempic), dulaglutide (Trulicity), insulin.
• Tirzepatide's dual mechanism shows promise for superior efficacy, potentially capturing significant market share.

Regulatory progress

• Trial results indicating superior HbA1c reduction and weight loss over semaglutide.
• Anticipated FDA approval provides a pathway for rapid commercial launch.

How does Tirzepatide compare financially to competitors?

Attribute	Tirzepatide	Semaglutide (Ozempic/Wegovy)	Dulaglutide (Trulicity)
Approval Year	Expected 2024	2017 (Ozempic), 2021 (Wegovy)	2014
Market Penetration	Pending (post-approval)	Strong, ~$6 billion annual sales	~$4 billion annual sales
Pricing (per dose)	Estimated at ~$25-$50	~$20-$60 (based on indication)	~$25
Peak Sales Estimate	$10–15 billion (2025-2030)	$15 billion (peak)	~$8 billion
Market Share Prospects	High, driven by efficacy and label expansion	Dominant, with continued growth	Mature, with potential plateau

Sales projections

• Early estimates by market analysts position Tirzepatide as capturing up to 20% of the incretin market within five years post-launch.
• Peak global sales could reach $12–15 billion, assuming rapid uptake and label expansion.

What are the potential market challenges?

Competition

• Established GLP-1 receptor agonists with strong brand recognition.
• Slow regulatory approval or delays could affect market entry.

Safety concerns

• Safety profile remains under review; any adverse events could limit commercialization.
• Gastrointestinal side effects are common among GLP-1 agents; Tirzepatide's safety margin needs further validation.

Pricing and reimbursement

• High-cost positioning may challenge payers.
• Reimbursement strategies will influence market penetration.

Financial trajectory considerations

Revenue potential

• Based on trial data, Tirzepatide could generate revenues comparable to or exceeding existing top-selling drugs in the same class.
• Launch in 2024, with initial sales ramping over 12–24 months.

Investment implications

• Eli Lilly has allocated $2 billion annually toward Tirzepatide development and commercialization.
• The company expects profitability within 3–5 years post-launch, depending on market uptake and reimbursement.

Market risks

• Competition from future oral incretins or novel mechanisms.
• Regulatory hurdles could delay commercialization.
• Pricing pressures as biosimilars or generics emerge in related classes.

Key Takeaways

• Tirzepatide's dual GLP-1/GIP mechanism shows potential for high efficacy in T2DM and obesity.
• Market dynamics favor rapid adoption if regulatory approval and safety profiles are confirmed.
• Peak sales are projected between $10 billion and $15 billion, with significant upside if label expansions occur.
• Competition remains strong from established GLP-1 drugs; differentiating efficacy and safety will be crucial.
• Reimbursement strategies and pricing negotiations will influence growth trajectory.

FAQs

1. When is Tirzepatide expected to receive FDA approval?
Approval is anticipated in late 2023 or early 2024, based on recent regulatory filings and trial results.

2. How does Tirzepatide compare to semaglutide in efficacy?
Clinical trials show Tirzepatide achieves greater HbA1c reduction and weight loss than semaglutide, indicating potential for superior efficacy.

3. What are the main risks for Tirzepatide's market success?
Risks include safety profile concerns, regulatory setbacks, pricing and reimbursement challenges, and stiff competition from existing drugs.

4. What are the projected peak sales for Tirzepatide?
Between $10 and $15 billion annually, depending on market penetration and label expansion.

5. How will Tirzepatide's market share evolve?
Initial uptake depends on regulatory approval, safety profile, and preference among prescribers. It could capture a significant portion of the incretin market within five years.

---

References

[1] International Diabetes Federation. (2023). IDF Diabetes Atlas, 10th Edition.
[2] MarketWatch. (2023). Outlook for Tirzepatide in T2DM and Obesity.
[3] Eli Lilly. (2022). Clinical Trial Data for Tirzepatide.